



Endologix  
Investor Relations Department  
2 Musick  
Irvine, CA 92618  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: ELGX

Last Trade:	4.05
Trade Time:	4:00 PM ET Feb 22, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	3.75 - 7.66
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- **Addressing a signi... [\(more\)](#)**

## Stock Performance



### Press Releases [\[ View all \]](#)

*Feb 21, 2018*

[John McDermott Steps Down as Chief Executive Officer of Endologix, Inc.](#)

*Feb 21, 2018*

[Endologix Reports Fourth Quarter and Fiscal Year 2017 Financial Results](#)

*Feb 5, 2018*

[Endologix, Inc. Completes Patient Enrollment in the ELEVATE IDE Clinical Study](#)

*Jan 30, 2018*

[Endologix, Inc. to Present at the Leerink Partners 7th Annual Global Healthcare Conference](#)

*Jan 29, 2018*

[Endologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

### Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

*Mar 1, 2017*

[Annual Report \(10-K\)](#)

*May 1, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 7, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 4, 2017*

[Quarterly Report \(10-Q\)](#)

*May 5, 2017*

[Quarterly Report \(10-Q\)](#)